BioSpace News Archive

TRACON Pharmaceuticals announced today that it has entered into a collaborative partnership agreement with Eucure Biopharma, a subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

CNS Pharmaceuticals Inc. today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”)

SI-BONE, Inc. announced that UnitedHealthcare has changed its minimally invasive SI joint fusion policy from covering all devices to exclusively covering SI-BONE’s triangular iFuse Implants, effective October 1, 2021.

atai Life Sciences announced the launch of PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout.

Sirtex Medical announced today that the first procedure of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres in China was successfully performed for a patient with hepatocellular carcinoma (HCC) on Sept. 28, 2021.

Kintara Therapeutics, Inc announces today that its Chief Executive Officer, Saiid Zarrabian , will present a corporate overview at the 14th Annual LD Micro Main Event Conference which is being held at the Luxe Sunset Bel-Air in Los Angeles from October 12 – 14, 2021.

Galmed Pharmaceuticals Ltd. announced today that the one-year results of the global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol in patients with NASH have been published in Nature Medicine (https://www.nature.com/articles/s41591-021-01495-3).

Fidmi Medical Ltd. ( www.fidmimedical.com ) has announced completion of a $2.2 million financing round and launched its FDA-cleared low-profile Percutaneous Endoscopic Gastrostomy (PEG) device in the U.S.

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Timothy J. Miller, Ph.D., CEO, President and Co-Founder, will discuss Forge’s robust AAV manufacturing solutions, proprietary technology advancements, and clinical development during a company presentation at Cell & Gene Meeting on the Mesa on October 12 at 5:00 p.m. PT.

Results for Glatiramer Acetate (GA) Depot Phase IIa study in patients with primary progressive multiple sclerosis, and novel anti-BMP for remyelination treatment in MS will be presented ECTRIMS 2021 Digital Experience will be held virtually Oct. 13-15, 2021